News

AbCheck licenses mAB technology
Enlarge image

BusinessCzech Republic

AbCheck licenses mAB technology

14.11.2012 - Plzen-based AbCheck s.r.o.has licensed an affinity maturation and antibody optimisation platform from US bioinformatics company Distributed Bio LCC.

Under the terms of the exclusive, worldwide agreement, AbCheck will apply Distributed Bio LCC’s proprietary computational library design algorithms to address the affinity maturation, therapeutic 'developability' and stability optimisation of antibodies in a one-step process.  According to the Czech antibody specialist, the platform of the US bioinformatics specialist makes it possible to deliver functional, "GMP ready", antibodies with significantly increased affinities with minimal mutations from fully human frameworks from its phage and yeast display antibody libraries

AbCheck CEO Volker Lang stressed: "By combining the strength of both technologies we have created a platform that exactly addresses current market needs.“ "Library design algorithms redefine the full potential of high throughput screening," said Jacob Glanville, Scientific Director of Distributed Bio. "Distributed Bio's library design algorithms encode years of protein engineering directly into the library designs. We are delighted to bring this technology forward with AbCheck: their leading edge expertise in antibody engineering and library development make them an ideal partner for introducing this new technology to the market.

Abcheck uses its AbSieve platform to develop antibodies for partners in all antibody formats, and its AbAccel algorithm for affinity maturation and optimisation. Distributed Bio provides antibody informatics, including: sequence & structural analysis; affinity maturation & humanisation; NextGen repertoire sequencing; phage display panning and library analysis.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/abcheck-licenses-antibody-technology.html

AwardFinlandEU

27.05.2016 The Finnish Technology Academy has awarded US-American innovator Frances Arnold the 2016 Millennium Technology Prize, worth €1m. Arnold is a pioneer in the field of directed evolution.

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Aachen

Biomedica 2016

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • 4SC (D)3.25 EUR8.33%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.50 SEK-7.56%
  • RENEURON (UK)3.50 GBP-5.41%
  • OXFORD BIOMEDICA (UK)5.62 GBP-4.91%

TOP

  • GALAPAGOS (B)52.00 EUR31.0%
  • NICOX (F)10.91 EUR25.0%
  • GENMAB (DK)1183.00 DKK21.8%

FLOP

  • MOBERG PHARMA (S)38.60 SEK-21.9%
  • BIONOR PHARMA (N)0.68 NOK-20.0%
  • BIOCARTIS GROUP NV (B)8.15 EUR-19.3%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)31.00 SEK1939.5%
  • NICOX (F)10.91 EUR480.3%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.50 SEK-88.6%
  • BB BIOTECH (D)43.82 EUR-84.7%
  • BIOTEST (D)17.14 EUR-78.0%

No liability assumed, Date: 27.05.2016